Paper Details

  1. Home
  2. Paper Details

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.

Author: CommoF, DessenP, KroemerG, LacroixL, LazarV, OlaussenK A, RazaS Q, RichonC, SoriaJ-C, TaillerM, VitaleI

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that pazopanib and lapatinib, two tyrosine kinase inhibitors, act synergistically to induce apoptosis of A549 non-small-cell lung cancer cells. The combination suppressed the activity of tyrosine kinases that were not or only partially affected by either of the two agents alone. These results suggest that combinations of tyrosine kinase inhibitors should be evaluated for synergistic antitumor effects.
Paper Details　
Original Abstract of the Article :
Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib). Pazopanib has also been reported to mediate inhibitory effect on a selected panel of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/onc.2009.277

データ提供：米国国立医学図書館（NLM）

Synergistic Proapoptotic Effects of Pazopanib and Lapatinib

[Cancer] is a complex and multifaceted disease, and finding effective treatments remains a crucial goal. This research explores the potential of combining two tyrosine kinase inhibitors, [pazopanib] and [lapatinib], to synergistically induce apoptosis in cancer cells.

Synergistic Anti-Cancer Effects: Combining Tyrosine Kinase Inhibitors

The study demonstrates that [pazopanib] and [lapatinib] act synergistically to [induce apoptosis] in [A549 non-small-cell lung cancer cells]. This synergistic effect was observed across a panel of unrelated human carcinoma cell lines, suggesting the potential of this combination therapy for treating various types of cancer.

Fighting Cancer: The Power of Combination Therapy

This research highlights the potential of [combination therapy] in enhancing cancer treatment efficacy. Just as a camel relies on multiple adaptations to thrive in the desert, we can leverage multiple therapeutic approaches to combat cancer. This study underscores the importance of exploring synergistic combinations of drugs to improve patient outcomes and enhance the fight against cancer.

Dr. Camel's Conclusion

Cancer research constantly seeks new and innovative ways to combat this devastating disease. This study demonstrates the potential of [combination therapy] using [pazopanib] and [lapatinib] to synergistically induce apoptosis in cancer cells, offering a promising new avenue for cancer treatment.
Date :
  1. Date Completed 2010-01-06
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

19749798

DOI: Digital Object Identifier

10.1038/onc.2009.277

Related Literature

Article Analysis
・Effects of pazopanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.